Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous Xingnaojing After Endovascular Therapy for Acute Ischemic Stroke
ChiCTR2100047647Phase 4Not yet recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2021
- Countries
- 1
01
Overview
Phase 4, randomised trial of Xingnaojing in ischemic stroke (2 arms), sponsored by Beijing Tiantan Hospital. Primary endpoint: Neurological prognosis at 90 days. Planned start Jan 2021; status: not yet recruiting.
02
Drugs
Xingnaojing
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on ChiCTR2100047647.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100047647.